Pancreatic cancer kills more than 90 percent of patients within five years of diagnosis. It is one of the hardest cancers to treat, and for decades, doctors have had few options to offer patients. A new pill, according to a report by PBS, may be on the way to changing that.
The cancer is so deadly in part because it is almost never caught early. The pancreas sits deep inside the body, and tumors there rarely cause symptoms until they have already spread. By the time most patients learn they are sick, surgery is no longer an option. That leaves chemotherapy and radiation, both of which have limited effectiveness against this particular cancer.
The new treatment being studied is an oral drug, meaning patients could take it as a pill rather than receiving it through an IV infusion at a clinic. That difference matters. Infusion-based chemotherapy requires repeated hospital or clinic visits, which can be exhausting for patients who are already seriously ill. A pill taken at home would reduce that burden significantly.
Researchers have been working to identify the specific genetic mutations that drive pancreatic cancer in different patients. A large share of pancreatic tumors carry a mutation in a gene called KRAS, which has historically been considered nearly impossible to target with drugs. Scientists spent decades calling it undruggable. Recent advances have changed that thinking, and the pill under development targets this mutation directly.
The drug works by blocking the KRAS protein that the mutated gene produces. When that protein is blocked, the cancer cells lose a key signal that tells them to keep dividing. Early trial results, as reported by PBS, have shown the drug can shrink tumors in some patients. Researchers are still studying how long those results last and which patients are most likely to benefit.
Pancreatic cancer receives less research funding than several other cancers that kill fewer people each year. Advocates have pushed for more attention to the disease, pointing out that survival rates have barely improved over the past several decades while other cancers have seen major gains. The development of a targeted oral therapy would represent a significant shift in how the disease is treated.
Clinical trials are continuing, and doctors caution that the drug is not yet approved or widely available. Researchers are working to determine the right dosage and to understand the drug's side effects over longer periods. For patients currently facing a pancreatic cancer diagnosis, standard treatments remain the primary option while trial results continue to come in.
